Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance Therapy
- 1 February 2011
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (2) , 365-371
- https://doi.org/10.1097/jto.0b013e3181fff142
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse PopulationJournal of Thoracic Oncology, 2010
- Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010
- Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry DatabasesJournal of Thoracic Oncology, 2010
- Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection of Patients for Maintenance TherapyJournal of Thoracic Oncology, 2010
- Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the LiteratureThe Oncologist, 2007
- Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004